



Date: 24.05.2021

To

Department of Corporate Service
BSE Limited
PJ Towers, Dalal Street,
Fort Mumbai-400001.
Dear Sir / Madam,

BSE Script Code: 524572

Subject: Outcome of Board Meeting – May 24, 2021

In Continuation to our intimation dated May 15, 2021 regarding the Board Meeting Notice, we would like to inform you that the Board of Directors (the “**Board**”) of **PHARMAIDS PHARMACEUTICALS LIMITED** (the “**Company**”) at its meeting held today i.e. Monday, May 24, 2021 has considered and approved the Audited Financial Results along with the Audit Report for the Quarter and Financial Year ended March 31, 2021 Pursuant to regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulation’) which has been duly reviewed and recommended by the Audit Committee.

We are enclosing herewith the audited financial results along with Audit Report signed by our Statutory Auditors, M/s. PPKG & Co, Chartered Accountants.

The Board Meeting Commenced at 2.00 PM and concluded at 3.30 PM.

Please take note of the same on your record.

Thanking You,

Yours faithfully
For **Pharmaids Pharmaceuticals Limited**

Padma
S. Padmaja Kalyani
Director (DIN: 03096445)





Pharmaids Pharmaceuticals Limited

Statement of Profit and Loss account for the Quarter ended 31st March, 2021

Rs. (In Lakhs)

	Particulars	Quarter Ended			Year ended	Year ended
		Audited			Audited	Audited
		March 31, 2021	December 31, 2020	March 31, 2020	March 31, 2021	March 31, 2020
1	Revenue	188.52	341.00	-	855.10	-
2	Other Income		-	-	2.63	-
3	Total Income	188.52	341.00	-	857.73	-
4	Expenses					
	a) Cost of Material Consumed		-	-		-
	b) Purchase of Stock in Trade	78.52	391.69	-	852.82	-
	c) Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	90.73	(57.35)	-	(36.91)	-
	d) Employee Benefit Expenses	2.36	1.18	0.46	4.43	2.28
	e) Finance Cost		-	-		0.08
	f) Depreciation and Amortisation Expenses	1.12	1.13	1.09	4.48	3.88
	g) Other Expenses	14.06	2.44	2.05	24.07	31.27
	Total Expenses	186.79	339.09	3.60	848.89	37.52
5	Profit/(loss) before Exceptional items and Tax	1.73	1.91	(3.60)	8.84	(37.52)
6	Exceptional Items		-	-		-
7	Profit/(loss) before tax	1.73	1.91	(3.60)	8.84	(37.52)
8	Tax expense:					
	(1) Current tax	(2.08)	0.95	-	-	-
	(2) Deferred tax	(0.49)	-	(40.87)	(0.49)	(40.87)
9	Profit (Loss) for the period from continuing operations	4.30	0.97	37.27	9.33	3.35
10	Profit/(loss) from discontinued operations			-		
11	Tax expense of discontinued operations			-		
12	Profit/(loss) from discontinued operations (after tax)			-		-
13	Profit/(loss) for the period	4.30	0.97	37.27	9.33	3.35
14	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss			-		-
	(ii) Income tax relating to items that will not be reclassified to profit or loss			-		-
	B (i) Items that will be reclassified to profit or loss			-		-
	(ii) Income tax relating to items that will be reclassified to profit or loss			-		-
	Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)			-		-
15						
16	Earnings per equity share Basic and Diluted	0.04	0.01	0.36	0.09	0.03

NOTES: 1. The above results were approved at the meeting of the Board of Directors held on May 24, 2021. 2. The Company operates in a single segment. 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. As per NCLT order dated 27-09-2019, Pharmaids Pharmaceuticals Limited undergone amalgamation with Emergent Bio Naturals Limited w.e.f 01-04-2018 as explained in Para 4 of the Auditor's Report. 5. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period. 6. During this pandemic, business operations and financial position has revealed that there has been no significant impact on company's financial results as at 31st March, 2021. However, the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor such impact to future economic conditions.

Place: Hyderabad
Date: 24-05-2021

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited



Padmaja
S. Padmaja Kalyani
Director

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW



Pharmoids Pharmaceuticals Limited


Balance Sheet as at 31st March, 2021

Rs. (In Lakhs)

	Particulars	Note No.	Figures as at the end of 31.03.2021	Figures as at the end of 31.03.2020
	1	2	3	4
1 ASSETS				
Non-current assets				
(a) Property, Plant and Equipment			3.98	8.31
(b) Capital work-in-progress			45.00	45.00
(c) Investment Property			-	-
(d) Goodwill			-	-
(e) Other Intangible assets			-	-
(f) Intangible assets under development			-	-
(g) Biological Assets other than bearer plants			-	-
(h) Financial Assets			-	-
(i) Investments			-	-
(ii) Trade receivables			75.85	75.85
(iii) Loans			665.88	643.35
(iv) Others (to be specified)			-	-
(i) Deferred tax assets (net)			35.06	34.58
(j) Other non-current assets			-	-
2 Current assets				
(a) Inventories			36.91	-
(b) Financial Assets			-	-
(i) Investments			-	-
(ii) Trade receivables			27.72	-
(iii) Cash and cash equivalents			20.03	2.18
(iv) Bank balances other than (iii) above			-	-
(v) Loans			-	36.55
(vi) Others (to be specified)			-	-
(c) Current Tax Assets (Net)			-	-
(d) Other current assets			1.06	-
Total Assets			911.50	845.82
EQUITY AND LIABILITIES Equity				
(a) Equity Share capital			1,026.88	1,026.88
(b) Other Equity			(174.24)	(183.57)
LIABILITIES				
1 Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings			-	-
(ii) Trade payables			-	-
(iii) Other financial liabilities (other than those specified in			-	-
(b) Provisions			-	-
(c) Deferred tax liabilities (Net)			-	-
(d) Other non-current liabilities			-	-
2 Current liabilities				
(a) Financial Liabilities				
(i) Borrowings			-	-
(ii) Trade payables			50.17	1.07
(iii) Other financial liabilities (other than those specified in			-	-
(b) Other current liabilities			8.69	1.44
(c) Provisions			-	-
(d) Current Tax Liabilities (Net)			-	-
Total Equity and Liabilities			911.50	845.82

Place: Hyderabad
Date: 24-05-2021

By the order of the Board of Directors
For Pharmoids Pharmaceuticals Limited


S. Padmaja Kalyani
Director
(DIN : 03096445)

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW




Pharmaids Pharmaceuticals Limited

Cash Flow Statement

Rs. (In Lakhs)

	Particulars	Figures as at the end of 31.03.2021 (Audited)	Figures as at the end of 31.03.2020 (Audited)
A	CASHFLOW FROM OPERATING ACTIVITIES:		
	Net Profit before Tax	8.84	(37.52)
	Adjustment for:		
	Depreciation and Amortization	4.48	3.88
	Interest Charged		0.00
	Interest Income		-
	Dividend Income/Gain on sale of Investments		-
	Provision / write off for doubtful trade receivables		-
	Deferred Tax		-
	Operating Profit before change in working capital	13.33	(33.64)
	Working capital changes:		
	Changes in Inventories	(36.91)	-
	Changes in Trade Receivables	(27.72)	13.12
	Change in Short term loans and advances	36.55	(36.55)
	Changes in Other current Assets	(1.06)	
	Changes in Trade payables	49.10	(14.89)
	Changes in Other liabilities	7.25	(3.06)
	Changes in Provisions		
	Cash generated from Operations	40.53	(75.02)
	Direct tax paid (Net of Refunds)		(0.27)
	Net Cash inflow from Operating Activities (A)	40.53	(74.75)
B	CASH FLOW FROM INVESTING ACTIVITIES:		
	Proceeds from Sale Asset		
	Government assistance		-
	Interest received		-
	Dividend Income /Gain on Sale of Investments received		-
	Purchase of property, plant & equipments, intangible assets and Capital Advance	(0.15)	(4.24)
	Intangible assets under development		
	Long term loans and Advances Given/(Repaid)	(22.53)	70.29
	Net Cash inflow from Investing Activities (B)	(22.68)	66.05
C	CASH FLOW FROM FINANCING ACTIVITIES:		
	Proceeds from borrowings		-
	Net increase/ (decrease) in working capital demand loans		-
	Payment of lease liabilities		-
	Increase in Restricted Bank Balances other than Cash & Cash Equivalents		-
	Dividends paid (including distribution tax)		-
	Interest and other finance costs (including borrowing cost capitalised)		(0.00)
	Net Cash inflow from Financing Activities (C)	-	(0.00)
I	Net (decrease)/increase in cash and cash equivalents (A+B+C)	17.85	(8.70)
II	a) Cash and Cash Equivalents at the beginning of the year	2.18	10.88
	b) Effect of Exchange difference on restatement of foreign currency cash and cash equivalents		
	c) Effect of Fairvalue change of investment held for Trading		
III	Cash and Cash Equivalents at the end of the year (I+II)	20.03	2.18
IV	Cash and Cash Equivalents at the end of the year		
	Balances with Banks	14.25	1.96
	Cash on Hand	5.77	0.22
	Total Cash and Cash Equivalents	20.03	2.18

Place: Hyderabad
Date: 24-05-2021

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

S. Padmaja Kalyani
Director
(DIN : 03096445)

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029 Ph: 040 - 40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

**INDEPENDENT AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE
RESULTS OF PHARMAIDS PHARMACEUTICALS LTD**

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited
Hyderabad

We have audited the annual financial results of PHARMAIDS PHARMACEUTICALS LTD ("the Company") for the year ended 31st March, 2021 ("annual financial results"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations"). Attention is drawn to the fact that the figures for the last quarter ended 31st March 2021 and the corresponding quarter ended in the previous year as reported in the annual financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit. These annual financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these annual financial results based on our audit of the annual financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the annual financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by the management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these financial results, except the sundry Debtors/Sundry Creditors/Receivables/Payables are subject to confirmation and reconciliation.

- a) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and



- b) Give a true and fair view of the net profit, other comprehensive income and other financial information for the year ended 31st March, 2021.

The Scheme of Amalgamation of Emergent Bio Naturals Limited (EBNL) with Pharmaids Pharmaceuticals Limited was approved by the National Company Law Tribunal vide its order dated 27th September, 2019. The certified copy of the NCLT order was filed with Registered of Companies on 12th October, 2019 consequently the Scheme became operative, and effective date is 1st April, 2018 (Appointed Date). The Company has accounted the Amalgamation as per Appendix C of IND AS 103 Business Combination, the financial information in respect of prior periods has been restated as if the business combination had occurred on April 1st, 2018.

The adjustments made to the previously issued financial information to give effect to the Scheme have been reviewed by us. Our report is not modified in respect of this matter.

Place: Hyderabad


Date: 24th May, 2021

UDIN: 21205140 AAAA IF6875

For PPKG & CO

Chartered Accountants

FRN No. 009655S



GIRDHARI LAL TOSHNIWAL

(Partner)

M. No. 205140



Pharmaids Pharmaceuticals Limited

Date: 24.05.2021

To

Department of Corporate Service

BSE Limited

PJ Towers, Dalal Street,

Fort Mumbai-400001.

Dear Sir / Madam,

BSE Script Code: 524572

Subject: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligation and Disclosure Requirements), Regulations, 2015

Declaration

I Sadhanala Padmaja Kalyani, Director of the company hereby declare that, The Statutory Auditors of the Company, M/s. PPKG & Co, Firm registration Number 009655S have issued an Audit Report with Unmodified Opinion on Audited Financial results of the Company for the Quarter and Year ended on 31st March 2021.

This Declaration is given in compliance of Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation 2016. Vide notification No. SEBI/LAD-NRO/GN/2016-17/00 dated May 25, 2016 and circular No. CIR/CFD/CMD/56/2016 dated May 25, 2016

Kindly take this declaration on your record.

Yours Sincerely,

For Pharmaids Pharmaceuticals Limited

Padma

S. Padmaja Kalyani
Director

